2013
Search results
1 hour ago · Myeloma occurs when normal plasma cells become cancerous or malignant, and multiply uncontrollably. “Multiple myeloma causes plasma cells to accumulate in the bone marrow, weakening and damaging the bone. This can result in bone pain and fracture, and can also lead to increased levels of calcium in the blood,” Dr Ooi added.
1 hour ago · Mpox doesn’t usually spread easily between people. Close contact with the virus from an infected person or animal - such as touching a lesion or contaminated object - is the main pathway. The ...
1 hour ago · Abstract. Purpose: Hypoxia mediates treatment resistance in solid tumors. We evaluated if oxygen-enhanced (OE)-MRI-derived hypoxic volume (HVMRI) is repeatable and can detect radiotherapy-induced hypoxia modification in HPV-associated oropharyngeal head and neck squamous cell cancer (HNSCC). Experimental Design: 27 patients were recruited prospectively between March 2021 and January 2024 ...
1 day ago · On August 14, the U.S. Food and Drug Administration (FDA) approved axatilimab-csfr (Niktimvo), a colony-stimulating factor–1 receptor–blocking antibody, for the treatment of chronic graft-vs-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. AGAVE-201.
4 hours ago · While most people will recover at home, some people are more at risk of severe disease or may require additional treatment, including immunocompromised people, children younger than 8 years old ...
1 hour ago · An area of Speech Pathology that isn’t often discussed is our role in the assessment, treatment and management of dysphagia, or swallowing difficulties. In this blog, I’ll share some insights into how online therapy is an efficient approach to dysphagia management intervention and how we can support our clients to maintain safety at mealtimes and fulfilling lives.
1 day ago · Aug 14, 2024, 4:06 pm. WEDNESDAY, Aug. 14, 2024 (HealthDay News) -- For patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs) in clinical practice, survival plateaus after three years and then decreases, according to a study published online Aug. 14 in JAMA Network Open.
